Pharmaceuticals, Biotechnology and Life Sciences
Promatix Biosciences presents preclinical data on PBS293-MMAE, a first-in-class bispecific ADC targeting EGFR and EphA2 in colorectal cancer.
South Korean pharmaceutical manufacturers are rapidly expanding capacity to support manufacturing of long‑acting obesity shots, signalling deeper integration with global…
With semaglutide patents nearing expiry in key markets, Indian manufacturers and partners are mobilizing to introduce lower‑cost GLP‑1 alternatives, tapping…
Novo Nordisk’s mid‑stage “triple G” obesity candidate UBT251 showed up to ~19.7 % mean weight loss in a Chinese phase 2…
Novo Nordisk reports up to 19.7% mean weight loss in Phase 2 trial of triple agonist UBT251, expanding its next-generation obesity pipeline.
Secarna to collaborate with Scenic to develop first-in-class disease-modifying oligonucleotide therapies for severe genetic diseases.
Bristol Myers Squibb and Bain Capital announced Monday the creation of a new independent biopharmaceutical company, called NewCo, which will…
Genflow Biosciences, the only publicly listed longevity company in Europe, has launched a new development program in ophthalmology, focused on…
Valneva SE, a specialty vaccine company, and LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases,…
Oncodesign Services has appointed Dr. Aidan Synnott as chief executive officer, to help strengthen its position as a trusted partner in drug discovery. The appointment reflects the company’s commitment to deepen client collaboration, enhance the quality of its science, and anticipate the evolving needs of the biopharma industry.